{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:35:59Z","timestamp":1789684559906,"version":"4.0.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jaad.2026.06.034","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:48:26Z","timestamp":1781308106000},"page":"1083-1094","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immune checkpoint inhibitor-associated autoimmune bullous disease: A clinical review"],"prefix":"10.1016","volume":"95","author":[{"given":"Houriah Y.","family":"Nukaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Barnawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husna Irfan","family":"Thalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Abdulrahman","family":"Basamih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sariya","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz G.","family":"Aljohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar Saed","family":"Aldien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Lazarowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika Bushatsky Andrade","family":"de Alencar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Wilson H.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Niaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0562-4675","authenticated-orcid":false,"given":"Ivan V.","family":"Litvinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jaad.2026.06.034_bib1","doi-asserted-by":"crossref","first-page":"834","DOI":"10.4103\/jcrt.JCRT_1241_20","article-title":"Cancer immunotherapy: recent advances and challenges","volume":"17","author":"Dhar","year":"2021","journal-title":"J Cancer Res Ther"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.034_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13045-017-0552-6","article-title":"Cancer immunotherapy beyond immune checkpoint inhibitors","volume":"11","author":"Marin-Acevedo","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.jaad.2026.06.034_bib3","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-16-0049","article-title":"Emerging opportunities and challenges in cancer immunotherapy","volume":"22","author":"Whiteside","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.034_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.autrev.2011.05.017","article-title":"Autoimmune blistering diseases of the skin","volume":"11","author":"Sticherling","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.034_bib5","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1590\/abd1806-4841.20199011","article-title":"Pemphigus vulgaris","volume":"94","author":"Porro","year":"2019","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib6","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An Bras Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.034_bib7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clindermatol.2011.03.010","article-title":"Dermatitis herpetiformis","volume":"30","author":"K\u00e1rp\u00e1ti","year":"2012","journal-title":"Clin Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.06.034_bib8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cac2.12178","article-title":"Advancing to the era of cancer immunotherapy","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.034_bib9","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jaad.2026.06.034_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.578091","article-title":"First-line immune-checkpoint inhibitors in non-small cell lung cancer: current landscape and future progress","volume":"11","author":"Huang","year":"2020","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib11","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/bjd.21836","article-title":"Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study","volume":"187","author":"Kawsar","year":"2022","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib13","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2023.1147513","article-title":"Mucocutaneous adverse events to immune checkpoint inhibitors","volume":"4","author":"Muhaj","year":"2023","journal-title":"Front Allergy"},{"key":"10.1016\/j.jaad.2026.06.034_bib15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.034_bib16","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jaad.2026.06.034_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fmed.2019.00249","article-title":"Paraneoplastic pemphigus revealed by anti-programmed death-1 pembrolizumab therapy for cutaneous squamous cell carcinoma complicating hidradenitis suppurativa","volume":"6","author":"Yatim","year":"2019","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"10.1016\/j.jaad.2026.06.034_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00262-025-04172-3","article-title":"The immunophenotype of immune checkpoint-induced bullous pemphigoid: a cohort study","volume":"74","author":"Saffuri","year":"2025","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib19","doi-asserted-by":"crossref","DOI":"10.5070\/D329662995","article-title":"Linear IgA bullous dermatosis associated with immunotherapy","volume":"29","author":"Momin","year":"2023","journal-title":"Dermatol Online J"},{"issue":"7","key":"10.1016\/j.jaad.2026.06.034_bib20","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.3390\/cancers15072084","article-title":"Cutaneous adverse reactions of immunotherapy in patients with advanced melanoma","volume":"15","author":"Nikolaou","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.034_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/skinhd\/vzae008","article-title":"Immune checkpoint inhibitor-associated linear IgA bullous dermatosis with recalcitrant ocular involvement: a rare presentation","volume":"5","author":"Saeed","year":"2025","journal-title":"Skin Health Dis"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.034_bib22","first-page":"9923","article-title":"Linear immunoglobulin A bullous dermatosis induced by atezolizumab","volume":"16","author":"Almutairi","year":"2024","journal-title":"Dermatol Rep"},{"key":"10.1016\/j.jaad.2026.06.034_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.034_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cden.2013.07.003","article-title":"Mucous membrane pemphigoid","volume":"57","author":"Xu","year":"2013","journal-title":"Dent Clin North Am"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/jdv.19582","article-title":"Anti-\u03b16\u03b24 integrin autoantibodies inhibit the binding of laminins to \u03b16\u03b24 integrin in patients with pemphigoid and affect the gastrointestinal tract","volume":"38","author":"Arase","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.034_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41415-024-7074-8","article-title":"The management of pemphigus vulgaris and mucous membrane pemphigoid in a joint oral medicine and dermatology clinic: a five-year narrative review","volume":"236","author":"Davis","year":"2024","journal-title":"Br Dent J"},{"key":"10.1016\/j.jaad.2026.06.034_bib27","article-title":"Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience","volume":"10","author":"Merli","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaad.2026.06.034_bib28","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2026.06.034_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1259071","article-title":"Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review","volume":"14","author":"Nakamura","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2026.06.034_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1363032","article-title":"State-of-the-art diagnosis of autoimmune blistering diseases","volume":"15","author":"van Beek","year":"2024","journal-title":"Front Immunol"},{"issue":"4-5","key":"10.1016\/j.jaad.2026.06.034_bib31","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.autrev.2014.01.047","article-title":"Diagnosis and classification of autoimmune blistering diseases","volume":"13","author":"Baum","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"12","key":"10.1016\/j.jaad.2026.06.034_bib32","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/ijms18122532","article-title":"Paraneoplastic pemphigus: insight into the autoimmune pathogenesis, clinical features and therapy","volume":"18","author":"Paolino","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2026.06.034_bib33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdcr.2021.02.012","article-title":"Paraneoplastic pemphigus manifesting in a patient treated with pembrolizumab for urothelial carcinoma","volume":"10","author":"McNally","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"10201","key":"10.1016\/j.jaad.2026.06.034_bib34","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(19)31778-7","article-title":"Pemphigus","volume":"394","author":"Schmidt","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.034_bib35","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1067\/mjd.2000.107488","article-title":"Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus","volume":"43","author":"Joly","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.034_bib36","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.285.5.652","article-title":"Prospects for autoimmune disease: research advances in pemphigus","volume":"285","author":"Anhalt","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2026.06.034_bib37","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3389\/fimmu.2019.01259","article-title":"Paraneoplastic pemphigus: paraneoplastic autoimmune disease of the skin and mucosa","volume":"10","author":"Kim","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.034_bib38","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bjd.12479","article-title":"Laboratory diagnosis of paraneoplastic pemphigus","volume":"169","author":"Poot","year":"2013","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.034_bib39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaad.2003.11.051","article-title":"Mucosal dominant pemphigus vulgaris with anti-desmoplakin autoantibodies","volume":"51","author":"Mimouni","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.06.034_bib40","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/cup.14004","article-title":"Paraneoplastic pemphigus: revised diagnostic criteria based on literature analysis","volume":"48","author":"Svoboda","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib41","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/sj.jid.5701041","article-title":"Transglutaminase autoantibodies in dermatitis herpetiformis and celiac sprue","volume":"128","author":"Marietta","year":"2008","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.annder.2024.103269","article-title":"Pruriginous vesicular eruption associated with nivolumab immunotherapy: a case of dermatitis herpetiformis","volume":"151","author":"Housset","year":"2024","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.19750","article-title":"Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors","volume":"185","author":"Gault","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.034_bib44","doi-asserted-by":"crossref","first-page":"751","DOI":"10.4103\/idoj.idoj_763_24","article-title":"Lichen planus pemphigoides: a clinical, histopathological, and immunological report of 12 Indian patients","volume":"16","author":"De","year":"2025","journal-title":"Indian Dermatol Online J"},{"key":"10.1016\/j.jaad.2026.06.034_bib45","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.3389\/fimmu.2019.01389","article-title":"Lichen planus pemphigoides: from lichenoid inflammation to autoantibody-mediated blistering","volume":"10","author":"H\u00fcbner","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2026.06.034_bib46","series-title":"Blistering diseases: clinical features, pathogenesis, treatment","first-page":"161","article-title":"Histological and immunofluorescence diagnosis of autoimmune blistering diseases","author":"Mascar\u00f3","year":"2015"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib47","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5858\/arpa.2019-0175-RA","article-title":"Classic findings, mimickers, and distinguishing features in primary blistering skin disease","volume":"144","author":"Tintle","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"10.1016\/j.jaad.2026.06.034_bib48","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1158\/2326-6066.CIR-18-0487","article-title":"The balancing act between cancer immunity and autoimmunity in response to immunotherapy","volume":"6","author":"Young","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.034_bib49","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/biomedicines11020323","article-title":"A review of bullous dermatologic adverse events associated with anti-cancer therapy","volume":"11","author":"Parisi","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.034_bib51","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1590\/abd1806-4841.20199165","article-title":"Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview","volume":"94","author":"Maruta","year":"2019","journal-title":"An Bras Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2026.06.034_bib52","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamadermatol.2022.1624","article-title":"Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review","volume":"158","author":"Asdourian","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2026.06.034_bib53","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/ijd.15627","article-title":"Linear IgA\/IgG bullous dermatosis after nivolumab therapy","volume":"60","author":"Perandones-Gonz\u00e1lez","year":"2021","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3389\/fimmu.2019.00034","article-title":"The diagnosis and blistering mechanisms of mucous membrane pemphigoid","volume":"10","author":"Kamaguchi","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.034_bib55","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jaad.2013.07.009","article-title":"Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid","volume":"69","author":"S\u00e1rdy","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib56","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fmed.2018.00296","article-title":"Diagnosis of autoimmune blistering diseases","volume":"5","author":"Witte","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.034_bib57","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3748","article-title":"Diagnostic value and practicability of serration pattern analysis by direct immunofluorescence microscopy in pemphigoid diseases","volume":"101","author":"Holtsche","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2026.06.034_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3389\/fmed.2018.00266","article-title":"The usefulness of indirect immunofluorescence in pemphigus and the natural history of patients with initial false-positive results: a retrospective cohort study","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.034_bib59","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40257-020-00584-2","article-title":"Dermatitis herpetiformis: an update on diagnosis and management","volume":"22","author":"Reunala","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib60","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.3389\/fimmu.2019.01974","article-title":"Serological diagnosis of autoimmune bullous skin diseases","volume":"10","author":"Saschenbrecker","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.jaad.2026.06.034_bib61","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaad.2019.03.077","article-title":"Anti-p200 pemphigoid is the most common pemphigoid disease with serum antibodies against the dermal side by indirect immunofluorescence microscopy on human salt-split skin","volume":"81","author":"Lau","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib62","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.clindermatol.2019.09.004","article-title":"Advances in the diagnosis of autoimmune bullous dermatoses","volume":"37","author":"Harrell","year":"2019","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib63","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/CCID.S158388","article-title":"Histologic characterization of cellular infiltration in autoimmune subepidermal bullous diseases in a tertiary hospital in Saudi Arabia","volume":"11","author":"BinJadeed","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib64","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2020.05.045","article-title":"Management of immune checkpoint inhibitor-induced bullous pemphigoid","volume":"84","author":"Apalla","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib65","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.clindermatol.2020.06.011","article-title":"Cutaneous immune-related adverse events to checkpoint inhibitors","volume":"38","author":"Malviya","year":"2020","journal-title":"Clin Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.034_bib66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40257-016-0235-z","article-title":"Paraneoplastic pemphigus and autoimmune blistering diseases associated with neoplasm: characteristics, diagnosis, associated neoplasms, proposed pathogenesis, treatment","volume":"18","author":"Kartan","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.06.034_bib67","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/1744666X.2020.1672535","article-title":"Treatment of pemphigus vulgaris: part 1 - current therapies","volume":"15","author":"Yanovsky","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.034_bib68","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jid.2018.10.010","article-title":"Dermatitis herpetiformis and celiac disease increase the risk of bullous pemphigoid","volume":"139","author":"Varpuluoma","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.034_bib69","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2022.06.1186","article-title":"Impact of biologic therapy on cancer outcomes in patients with immune checkpoint inhibitor-induced bullous pemphigoid","volume":"88","author":"Said","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.06.034_bib70","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf208","article-title":"Immuno-oncologyDupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series","volume":"30","author":"Nykaza","year":"2025","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib71","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1393134","article-title":"Eosinophils: the unsung heroes in cancer?","volume":"7","author":"Varricchi","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jaad.2026.06.034_bib72","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S142471","article-title":"Emerging treatment options for the management of pemphigus vulgaris","volume":"14","author":"Kridin","year":"2018","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"10.1016\/j.jaad.2026.06.034_bib73","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1007\/s10147-025-02797-z","article-title":"Impact of medications on the efficacy of immune checkpoint inhibitors in patients with recurrent or metastatic head and neck cancer","volume":"30","author":"Minohara","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.034_bib74","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.953546","article-title":"Hemidesmosomal reactivity and treatment recommendations in immune checkpoint inhibitor-induced bullous pemphigoid-A retrospective, monocentric study","volume":"13","author":"Schauer","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2026.06.034_bib76","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.2147\/CCID.S487711","article-title":"Successful treatment of immune checkpoint inhibitor-induced bullous pemphigoid with omalizumab: a case report and review of the literature","volume":"17","author":"Chen","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib77","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jdcr.2025.03.021","article-title":"Pemphigoid diseases as immune-related adverse effect following immune checkpoint inhibitors: a clinical case series of a diverse spectrum","volume":"61","author":"Kotnik","year":"2025","journal-title":"JAAD Case Rep"},{"issue":"8","key":"10.1016\/j.jaad.2026.06.034_bib78","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/ijd.17626","article-title":"Treatment of pembrolizumab-induced bullous pemphigoid with dupilumab: a case report and review of the literature","volume":"64","author":"Barghi","year":"2025","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib79","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jdcr.2024.11.033","article-title":"Immune checkpoint inhibitor induced bullous pemphigoid treated by dupilumab: a case series","volume":"57","author":"Bogdanski","year":"2025","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib80","doi-asserted-by":"crossref","DOI":"10.5070\/D328257396","article-title":"A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab","volume":"28","author":"Bruni","year":"2022","journal-title":"Dermatol Online J"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib81","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.jaad.2022.08.001","article-title":"A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes","volume":"87","author":"Bur","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib82","article-title":"Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med Case Rep"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.034_bib83","first-page":"587","article-title":"Successful treatment of checkpoint inhibitor-associated bullous pemphigoid with dupilumab in a patient with angiosarcoma","volume":"22","author":"Hansen","year":"2024","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib84","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/cup.14383","article-title":"Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma","volume":"50","author":"Khazaeli","year":"2023","journal-title":"J Cutan Pathol"},{"issue":"9","key":"10.1016\/j.jaad.2026.06.034_bib85","doi-asserted-by":"crossref","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol Online J"},{"issue":"8","key":"10.1016\/j.jaad.2026.06.034_bib86","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: a case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.034_bib87","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/skinhd\/vzae023","article-title":"A case of pembrolizumab-induced bullous pemphigoid treated with dupilumab","volume":"5","author":"Rossi","year":"2025","journal-title":"Skin Health Dis"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.034_bib88","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/lary.31743","article-title":"Pembrolizumab-associated bullous pemphigoid with laryngeal involvement","volume":"135","author":"Triantafillou","year":"2025","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jaad.2026.06.034_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2023.09.041","article-title":"The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: a single-institution real-life study","volume":"43","author":"Young","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.034_bib90","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12885-017-3921-1","article-title":"Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization","volume":"18","author":"Xing","year":"2018","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib91","first-page":"872","article-title":"Clinical features of Chinese patients with bullous pemphigoid induced by immune checkpoint inhibitors","volume":"46","author":"Li","year":"2024","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib92","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2023.10.012","article-title":"Use of omalizumab is associated with improvement of pruritic skin disorders induced by immune checkpoint inhibitors: a retrospective cohort from the European Task Force of Dermatology for Cancer patients","volume":"90","author":"Alamon-Reig","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib93","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2026.06.034_bib94","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2026.06.034_bib95","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ajd.13960","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: a case series of 13 patients","volume":"64","author":"Yun","year":"2023","journal-title":"Australas J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2026.06.034_bib96","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-024-00866-z","article-title":"The use of biologic agents for the treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors: a review of reported cases","volume":"25","author":"Pach","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2026.06.034_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-253059","article-title":"Two rare cases of bullous pemphigoid associated with immune checkpoint inhibitors","volume":"15","author":"Mazumder","year":"2022","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.jaad.2026.06.034_bib98","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jaad.2025.04.075","article-title":"The treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors with biologic therapy: a single-institution retrospective study at a tertiary care cancer center","volume":"93","author":"Greenberg","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2026.06.034_bib99","doi-asserted-by":"crossref","first-page":"e591","DOI":"10.1111\/jdv.17321","article-title":"Treatment-resistant bullous pemphigoid developing during therapy with immune checkpoint inhibitors","volume":"35","author":"Povilaityte","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.jaad.2026.06.034_bib100","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamadermatol.2017.0091","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2026.06.034_bib101","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1200\/JOP.19.00751","article-title":"Pembrolizumab-induced bullous pemphigoid treated with rituximab","volume":"16","author":"Sharma","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jaad.2026.06.034_bib102","article-title":"Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers","volume":"11","author":"Sadik","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jaad.2026.06.034_bib103","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/ijd.13970","article-title":"Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid","volume":"57","author":"Ridpath","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2026.06.034_bib104","article-title":"Case report: prurigo nodularis-like linear IgA\/IgG bullous dermatosis: a case report and literature review","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226028884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226028884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T10:58:13Z","timestamp":1789642693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226028884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0190962226028884"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.034","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune checkpoint inhibitor-associated autoimmune bullous disease: A clinical review","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.06.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}